ARTICLES BY BIKASH CHATTERJEE

• Emerging Trends In mAbs Manufacturing In 2025 And Beyond

  2/11/2025

  Two key innovations — continuous perfusion in upstream processing and multicolumn chromatography in downstream processing — are having a profound impact on biologics manufacturing.

• CMC And Quality Considerations When Engaging Your CDMO

  3/21/2022

  Before pursuing an outsourcing strategy, it is essential to define what processes will be kept in-house and where your CDMO partner will take the lead.

• FDA's 2021 Focus Areas Of Regulatory Science: 5 Trends To Watch

  3/19/2021

  Examine key elements from the report “Advancing Regulatory Science at FDA: FARS” that provide meaningful regulatory insight on new and emerging approaches to drug development and governance.

• FDA Steps Up Support For Advanced Manufacturing Technologies

  2/22/2021

  Examine the potential of the FDA and NIST's MOU to provide critical technical guidance that could greatly standardize the approaches to implementing AMTs, such as those used in continuous manufacturing.

• Navigating The FDA's Emergency Use Authorization Process

  5/14/2020

  The FDA has been authorized to grant Emergency Use Authorizations for SARS-CoV-2. This will impact both internal manufacturing and the CDMOs that drug sponsors employ. 

• Ensuring Quality In Ventilator Production Scale-Up For COVID-19

  4/24/2020

  Chief Editor Louis Garguilo asked Outsourced Pharma Advisory Board member and COO/CSO of Pharmatech Associates, Inc., Bikash Chatterjee, to update our readers periodically on what he is seeing and experiencing during this coronavirus pandemic. This is his first update.

• Business Continuity & The Coronavirus: Are Your Pharma Operations At Risk?

  3/4/2020

  In the face of a pandemic, the value of a robust business continuity plan cannot be overstated. Organizations should actively evaluate those plans, focusing on service providers and partners. 

• New FDA Draft Guidance: Qualification Process For Drug Development Tools

  2/3/2020

  The FDA recently issued its draft guidance on the qualification process for drug development tools (DDTs), as part of the commitment mandated by the 21^st Century Cures Act. The draft guidance provides a high-level description of the intent and content of the DDT program, but it does not address evidentiary standards or performance criteria for purposes of DDT qualification, leaving it to industry to propose the scientific argument and data package.

• Understanding The FDA's KASA Framework

  10/30/2019

  The FDA's Knowledge-Aided Assessment & Structured Application Framework marks an ambitious step forward in standardizing and increasing the efficiency of the drug review process. Here's what it will take for the framework to succeed. 

• Pharma 4.0: Building Quality Into Pharma Manufacturing, From Molecule To Medicine

  10/1/2019

  A race is being run to create the pharmaceutical manufacturing of the future and with Pharma 4.0, powerful market trends are shaping the running field.